Universal Screening for Familial Hypercholesterolemia in Children  by Klančar, Gašper et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 1 1 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 7 . 0 1 7Universal Screening for
Familial Hypercholesterolemia in Children
Gasper Klancar, BSC,*y Urh Groselj, MD,* Jernej Kovac, PHD,y Nevenka Bratanic, MD,* Natasa Bratina, MD,*
Katarina Trebusak Podkrajsek, PHD,yz Tadej Battelino, MD*xABSTRACTFro
jan
Slo
Pe
tio
au
Lis
MaBACKGROUND Individuals with familial hypercholesterolemia (FH) who are untreated have up to 100-fold elevated
risk for cardiovascular complications compared with those who are unaffected. Data for identiﬁcation of FH with a uni-
versal screening for hypercholesterolemia in children are lacking.
OBJECTIVES This study sought genetic identiﬁcation of FH from a cohort of children with elevated serum total
cholesterol (TC) concentration, detected in a national universal screening for hypercholesterolemia.
METHODS Slovenian children born between 1989 and 2009 (n ¼ 272) with TC >6 mmol/l (231.7 mg/dl) or >5 mmol/l
(193.1 mg/dl) plus a family history positive for premature cardiovascular complications, identiﬁed in a national universal
screening for hypercholesterolemia at 5 years of age were genotyped for variants in LDLR, PCSK9, APOB, and APOE.
RESULTS Of the referred children, 57.0% carried disease-causing variants for FH: 38.6% in LDLR, 18.4% in APOB, and
none in PCSK9. Nine novel disease-causing variants were identiﬁed, 8 in LDLR, and 1 in APOB. Of the remaining partic-
ipants, 43.6% carried the APOE E4 isoform. Estimated detection rate of FH in the universal screening program from 2009
to 2013 was 53.6% (95% conﬁdence interval [CI]: 34.5% to 72.8%), peaking in 2013 with an upper estimated detection
rate of 96.3%. Variants in LDLR, APOB, or the APOE E4 isoform occurred in 48.6%, 60.0%, and 76.5%, respectively, of
patients with a family history negative for cardiovascular complications.
CONCLUSIONS Most participants who were referred from a national database of universal screening results for hy-
percholesterolemia had genetically conﬁrmed FH. Data for family history may not sufﬁce for reliable identiﬁcation of
patients through selective and cascade screening. (J Am Coll Cardiol 2015;66:1250–7) © 2015 by the American College
of Cardiology Foundation.I ndividuals with untreated familial hypercholes-terolemia (FH) have up to 100-fold increasedrisk for developing atherosclerosis and cardio-
vascular disease in early adulthood compared with
unaffected individuals (1). Early diagnosis and man-
agement reduce this risk (2,3). The prevalence of
FH in the general population is estimated to be
between 1 in 200 (4,5) and 1 in 500 (4). FH is an auto-
somal dominant disorder clinically diagnosed by
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AB BR E V I A T I O N S
AND ACRONYM S
APOB = apolipoprotein B
APOE = apolipoprotein E
FH = familial
hypercholesterolemia
HDL = high-density lipoprotein
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1251and a ligand for the LDL receptor (9), whereas PCSK9
regulates LDL receptor membrane concentration (10).
Additionally, the interaction of common small-effect
LDL cholesterol-elevating alleles in various genes
may contribute to multifactorial disease development
(11,12), with the apolipoprotein E (APOE) E4 isoform
being the most recognized multivariant cause of
hypercholesterolemia (13).SEE PAGE 1258
LDL = low-density lipoprotein
LDLR = low-density
lipoprotein receptor
NGS = next-generation
sequencing
PCSK9 = proprotein
convertase subtilisin/kexin
type 9
TC = total cholesterol
TG = triglycerideVarious screening strategies have been proposed to
identify children with FH. Only implementations of
partial (14) and selective screenings primarily on the
basis of family history are reported (15). These ap-
proaches lack the strength of identifying patients
without known family history. Therefore, the National
Heart, Lung, and Blood Institute (16), the National
Lipid Association Expert Panel (17), and the European
Expert Panel (15) proposed universal screening as
a preferred method of screening for hypercholes-
terolemia in primary prevention efforts. Slovenia
(population 2 million) started universal screening
for hypercholesterolemia in 5-year-old children in
1995 (15). Screening was gradually implemented
throughout the whole country (18), reaching an esti-
mated majority of 5-year-old children (approximately
20,000) during 2013. Data for the efﬁcacy of a national
universal screening for detection of FH are lacking.
We sought to identify individuals with FH from a
cohort with elevated serum TC levels detected in the
Slovenian national universal screening for hyper-
cholesterolemia in 5-year-old children.
METHODS
STUDY POPULATION AND DESIGN. Measurement
of fasting serum TC was part of the national
programmed routine examination of 5-year-old
children by primary pediatricians (Slovenia national
universal screening for hypercholesterolemia)
(Central Illustration). According to national guide-
lines, participants with either a serum TC level of >6
mmol/l (231.7 mg/dl) without a family history of
premature cardiovascular complications or with a TC
level of >5 mmol/l (193.1 mg/dl) with a family history
positive for premature cardiovascular complications
(18) were referred after a consultation with their
parents to a tertiary pediatric outpatient clinic. Data
for participants’ family histories were obtained in
direct structured conversations with the parents.
Participants’ weight, body mass index, serum lipid
proﬁle (TC, LDL, high-density cholesterol [HDL],
triglyceride [TG]), and whole-blood samples for
targeted, next-generation sequencing (NGS) wereobtained at the tertiary pediatric outpatient
clinic. Simon Broome Register criteria (1)
were used for assessment of family history.
Positive family history was deﬁned as
myocardial infarction before 50 years of age
in any second-degree relative or before
60 years of age in any ﬁrst-degree relative
or as TC >7.5 mmol/l (289.6 mg/dl) in any
ﬁrst- or second-degree relative (ﬁrst-degree
relation included parent, offspring or sibling;
second-degree relation included grandparent,
grandchild, nephew, niece, or half-sibling).
Written informed consent was obtained from
all parents or legal guardians. Principles of
the Declaration of Helsinki were followed,
and the Slovenian National Medical Ethics
Committee approved the study (numbers
25/12/10 and 63/07/13).DNA SEQUENCING AND ANALYSIS. Genomic DNA
was isolated from whole-blood samples according
to established laboratory protocols using FlexiGene
isolation kit (Qiagen, Hilden, Germany). NGS is a
high-throughput method based on simultaneous se-
quencing of numerous candidate genes or genomic
intervals in a parallel fashion, effectively balancing
cost and data quality for population-targeted
sequencing studies (19). Samples for NGS were pre-
pared following the manufacturer’s protocol using
ADH MASTR ready-to-use NGS-based molecular assay
(Multiplicom NV, Niel, Belgium) for detection of vari-
ants in 4 genes associated with FH (encompassing
coding and promoter regions of LDLR, PCSK9, APOE
and part of APOB exon 26). Samples were sequenced
using a MiSeq sequencer with MiSeq reagent kit
version 2 (Illumina, San Diego, California) following
the manufacturer’s protocol, including recommen-
dations for quality control parameters. The presence of
copy number variations in LDLR was analyzed using
NextGENe (Softgenetics, State College, Pennsylvania)
and conﬁrmed by Multiplex ligation-dependent probe
ampliﬁcation with an LDLR-P062 kit (MRC-Holland,
Amsterdam, the Netherlands). Variants reported in
disease-speciﬁc databases (20) and the Human Gene
Mutation Database (HGMD) (Institute of Medical Ge-
netics, School of Medicine, University of Cardiff, Car-
diff, Wales) as unequivocally disease-causing were
classiﬁed as pathogenic. In silico analysis of novel
variants was performed with PolyPhen-2 (Harvard
University, Cambridge, Massachusetts), SIFT (J. Craig
Venter Institute, San Diego, California), and Muta-
tionTaster (University of Medicine, Berlin, Germany)
bioinformatic tools. Variants declared to be disease-
associated by at least 2 analytical algorithms were
CENTRAL ILLUSTRATION Detection of Familial Hypercholesterolemia From a Universal National Screening for
Hypercholesterolemia in Children
YN
UNIVERSAL NATIONAL SCREENING
National programmed routine examination of 5-year-old children by primary pediatricians
Does child have either:
Serum total cholesterol (TC) level of more than 6 mmol/l (231.7 mg/dl) without family history of cardiovascular (CV) complications
or
Serum TC level of more than 5 mmol/l (193.1 mg/dl) with family history of CV complications?
REFERRAL FOR TARGETED NEXT-GENERATION SEQUENCING 
 Genomic DNA sequencing and analysis from whole blood sample for detection
of variants in 4 genes associated with familial hypercholesterolemia (FH)
(the coding and promoter regions of LDLR, PCSK9, APOE genes, and part of the APOB exon 26)
No further 
tests
Consider additional 
genetic analysis
Familial hypercholesterolemia confirmed
Disease-causing genetic variant identified
in those referred from the universal screening
(Between 2009–2013, 57% of children referred for 
next-generation sequencing were diagnosed with FH. 
Of these children, only 40.6% had a family history
of CV complications proving that family history alone 
may not suffice for reliable identification of patients) 
Use early diagnosis to manage and reduce risk for developing
atherosclerosis and cardiovascular disease in early adulthood
Multifactoral
hypercholesterolemia 
confirmed
Disease-associated 
genetic variant 
identified in those 
referred from the 
universal screening
Negative
for genetic variants
No disease-causing or 
disease-associated 
genetic variant 
identified in those 
referred from the 
universal screening
Proposed Universal National Screening for Familial Hypercholesterolemia (FH) in Primary Prevention Efforts
KlanČar, G. et al. J Am Coll Cardiol. 2015; 66(11):1250–7.
A national universal screening for hypercholesterolemia in children 5 years of age (referral criteria: serum total cholesterol [TC] level >6 mmol/l
[231.7 mg/dl] without a family history of premature cardiovascular (CV) complications, or serum TC level >5 mmol/l [193.1 mg/dl] together with a family
history of premature cardiovascular complications) identiﬁed a disease-causing genetic variant for familial hypercholesterolemia (FH) in 57.0% of children,
with an additional one-ﬁfth identiﬁed with the most common multifactorial form of hypercholesterolemia, amounting to >75.0% of referred participants
carrying a disease-causing or disease-associated genetic variant. Assuming the commonly reported FH incidence numbers, the predicted detection rate from
the data for the previous 5 years (2009 to 2013) was 53.6% (95% conﬁdence interval [CI]: 34.5% to 72.8%), reaching its peak in 2013 (children born in
2008), with an upper estimated detection rate of 96.3% for an incidence of 1 in 500; nevertheless, when a greater incidence of 1 in 200 was assumed, the
upper estimated detection rate was only 38.5%. Relative risk (RR) of having the disease-causing genetic variant when a participant had a CV-positive
familial history was 1.53 (RR: 1.529; 95% CI: 1.25 to 1.88; p ¼ 0.0001). APOB ¼ presence of disease-causing variant in the apolipoprotein B gene; APOE E4
isoform ¼ presence of disease-associated variant in the apolipoprotein E gene; LDLR ¼ presence of disease-causing variant in the LDL receptor gene;
Other ¼ no presence of disease-causing or -associated variant in LDLR, APOB, PCSK9, or APOE.
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nucleotide variants and small duplications/deletions
with potentially disease-causing effect were con-
ﬁrmed by targeted Sanger DNA sequencing.
STATISTICAL ANALYSIS. Descriptive statistics (means,
standard deviations, and ratios) were used to charac-
terize the investigated population. Assumption of
equal proportions of detected FH population and
total population enrolled in the national universalscreening was made on the basis of the reported
incidence, number of referred children, and number
of live-born children publicly available at the Statis-
tical Ofﬁce of the Republic of Slovenia to estimate
approximate number of children enrolled in the uni-
versal screening program in the previous 5 years (2009
to 2013), as exact data were not available. The detec-
tion rate of the universal screening in the studied
population was evaluated by the number of children
TABLE 1 Clinical and Genetic Characteristics of the Study Cohort
Study Cohort
Familial Hypercholesterolemia*
n ¼ 155 (57.0%)
Multifactorial Hypercholesterolemia
n ¼ 117 (43.0%)
LDLR APOB APOE E4 Isoform Other†
Patients 272 (100.0) 105 (38.6) 50 (18.4) 51 (18.7) 66 (24.3)
Female 149 (54.8) 45 (42.9) 18 (36.0) 24 (47.1) 35 (53.0)
At universal screening for hypercholesterolemia at 5 years of age
TC, mmol/l 7.0  3.4 7.9  1.2 7.2  0.8 6.7  0.8 6.6  0.9
TC, mg/dl 258.7  131.3 305.0  46.3 278.0  30.9 258.7  30.9 254.8  34.8
Family history‡
Positive 90 (33.1) 46 (43.8) 17 (34.0) 11 (21.6) 13 (19.7)
Negative 168 (61.8) 51 (48.6) 30 (60.0) 39 (76.5) 51 (77.3)
Data NA 14 (5.1) 8 (7.6) 3 (6.0) 1 (2.0) 2 (3.0)
At ﬁrst evaluation at the tertiary outpatient clinic
Age, yrs 7.3  3.1 7.0  3.2 7.4  3.4 7.6  2.9 7.7  2.9
BMI 0.6  1.2 0.5  1.2 0.3  1.2 0.6  1.3 0.7  1.4
TC, mmol/l 6.5  1.2 7.3  1.2 6.6  0.9 5.9  0.7 5.7  0.8
TC, mg/dl 251.0  46.3 281.9  46.3 354.8  34.8 216.2  27.0 220.1  30.9
LDL, mmol/l 4.6  1.2 5.4  1.3 4.7  0.8 3.8  0.7 3.7  0.8
LDL, mg/dl 177.6  46.3 208.5  50.2 181.5  30.9 146.7  27.0 142.9  30.9
HDL, mmol/l 1.5  0.4 1.4  0.4 1.4  0.3 1.5  0.4 1.5  0.3
HDL, mg/dl 57.9  15.4 54.1  15.4 54.1  11.6 57.9  15.4 57.9  11.6
Non-HDL, mmol/l 5.1  1.2 5.8  1.2 5.2  0.8 4.4  0.7 4.2  0.9
Non-HDL, mg/dl 196.9  46.3 223.9  46.3 200.8  30.9 169.9  27.0 162.2  34.8
TG, mmol/l 1.2  0.8 1.1  0.6 1.2  0.9 1.3  0.9 1.2  0.8
TG, mg/dl 106.2  70.8 97.4  53.1 106.2  79.7 115.1  79.7 106.2  70.8
Values are n (%) or mean  SD. Non-HDL was calculated as [total cholesterol  HDL]. SI conversion factors: to convert TC, LDL, HDL, and non-HDL to mg/dl, multiply by 38.61.
To convert TG to mg/dl, multiply by 88.50. *No participants had disease-causing variants in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene. †No presence of
disease-causing or disease-associated variants in the LDLR, APOB, PCSK9, or APOE gene was found. ‡Simon Broome Register criteria (1) were used for assessment of family
history. Positive family history was deﬁned as myocardial infarction before 50 years of age in any second-degree relative or before 60 years of age in any ﬁrst-degree relative or
as serum TC concentration of >7.5 mmol/l (289.6 mg/dl) in any ﬁrst- or second-degree relative (ﬁrst-degree relatives included parent[s], offspring, or sibling; second-degree
relatives includes grandparent, grandchild, nephew, niece, or half-sibling).
APOB ¼ presence of disease-causing variant in the apolipoprotein B gene; APOE E4 isoform ¼ presence of disease-associated variant in the apolipoprotein E gene; BMI ¼
body mass index; HDL ¼ high-density cholesterol; LDLR ¼ presence of disease-causing variant in the LDL receptor gene; LDL ¼ low-density cholesterol, NA ¼ not available;
non-HDL ¼ non-high-density cholesterol; TC ¼ total cholesterol; TG ¼ triglyceride.
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1253per generation referred to the tertiary outpatient
clinic compared to the potential FH population esti-
mated from the registry of live-born children and was
reported as 1 in 500 and 1 in 200 incidence of FH (4,5).
Data deviation from normal was evaluated with the
D’Agostino and Pearson omnibus normality test. Dif-
ferences in disease-associated variant accumulation
between different groups of participants (sex and
cardiovascular-positive family history), correspond-
ing odds ratio (OR) and/or relative risk (RR), were
evaluated using Fisher exact test for 2  2 contingency
tables. Logistic regression model was applied (21) to
calculate OR and RR with corresponding 95% conﬁ-
dence intervals (CIs). Genotype-associated differ-
ences among TC, LDL, HDL, and non-HDL levels and
standard deviation score of body mass index were
statistically evaluated using Kruskal-Wallis test with
Dunn’s multiple comparisons test. A p value <0.05
was used as an indicator of statistical signiﬁcance. All
statistical calculations were made in Prism version
6.01 software (GraphPad, Inc., La Jolla, California).RESULTS
Altogether, 272 unrelated participants born between
1989 and 2009 were included in the study. Charac-
teristics of participants are shown in Table 1. Serum
TC levels at universal screening for hypercholester-
olemia at age 5 and fasting lipid proﬁle (TC, LDL,
HDL, and TG levels) were measured at ﬁrst admission
to a tertiary pediatric outpatient clinic. Participants
were referred to the tertiary pediatric outpatient
clinic at 7.3  3.1 years of age. A cardiovascular
complications-positive family history according to
Simone Broome Register criteria was identiﬁed in
33.1% of participants.
PREDICTION OF NATIONAL UNIVERSAL SCREENING
DETECTION RATE. The national universal screening
in Slovenia was introduced gradually, and the re-
ferral rate to the tertiary institution reached its ex-
pected level only in 2013. An estimated 33,000 to
70,000 of 96,690 live-born children were enrolled at
TABLE 2 Novel Heterozygous Disease-Causing Variants in LDLR and APOB
Gene
Number of
Variants (%)
Nucleotide
Change Protein Change Localization Protein Domain
In Silico Novel Variant Analysis
SIFT Prediction (Score) PolyPhen-2 Prediction (Score) MutationTaster
LDLR 2 (1.9) c.300C > G p.Asp100Glu Exon 3 LDL receptor class A2 Deleterious (0) Probably damaging (0.982) Disease causing
LDLR 1 (1.0) c.408C > T p.Asp136Asp‡ Exon 4 LDL receptor class A3 NA NA Disease causing
LDLR 1 (1.0) c.827G > T p.Cys276Phe Exon 6 LDL receptor class A7 Deleterious (0) Probably damaging (0.996) Disease causing
LDLR 1 (1.0) c.972C > G p.Gly324Gly‡ Exon 7 EGF-like 1 NA NA Disease causing
LDLR 1 (1.0) c.1470G > T p.Trp490Cys Exon 10 LDL receptor class B3 Deleterious (0) Probably damaging (1) Disease causing
LDLR 1 (1.0) c.1587-1G > C* NA Intron 10 NA NA NA NA
LDLR 1 (1.0) c.1706-1G > C† NA Intron 11 NA NA NA NA
APOB 1 (2.0) c.10370C > G p.Ser3457Cys Exon 26 LDLR binding side Deleterious (0.03) Probably damaging (0.976) Polymorphism
Double heterozygous
LDLR 1 (1.0) c.58G>A§ p.Gly20Arg Exon 1
c.1487G>A p.Gly496Asp Exon 10 LDL-receptor class B3 Deleterious (0.02) Probably damaging (0.998) Disease causing
*Variant c.1587-1G> A at the same location is disease-causing according to a disease-speciﬁc database (19) and the Human Gene Mutation Database (HGMD; Institute of Medical Genetics, School of Medicine,
University of Cardiff, Cardiff, Wales). †Variants c.1706-1G > A and c.1706-1G > T at the same location are disease-causing according to a disease-speciﬁc database (19) and the HGMD database. ‡Variant is
predicted to have potential alterations on splicing by Human Splicing Finder. §Known disease-causing variant.
Abbreviations as in Table 1.
Klancar et al. J A C C V O L . 6 6 , N O . 1 1 , 2 0 1 5
Familial Hypercholesterolemia in Children S E P T E M B E R 1 5 , 2 0 1 5 : 1 2 5 0 – 7
12545 years of age in the national universal screening
from 2009 to 2013. Assuming an FH incidence of 1 in
500, the predicted detection rate from the data for
the previous 5 years (2009 to 2013) was 53.6% (95% CI:
34.5% to 72.8%), reaching its peak in 2013 (children
born in 2008) with an upper estimated detection rate
of 96.3%. Assuming a greater incidence of 1 in 200,
the upper estimated detection rate was only 38.5%.
GENETIC CHARACTERIZATION. Of 272 participants,
105 (38.6%) had heterozygous disease-causing vari-
ants in LDLR, 50 (18.4%) in APOB, and none in PCSK9.
Twenty-three known (Online Table 1) and 8 novel
disease-causing variants (Table 2) were identiﬁed in
LDLR. Six novel disease-causing variants were
missense and 2 were intronic. Four participants had
multiple variants, 2 combinations of known disease-
causing variants (Online Table 1) and 1 combination
of a known and a novel disease-causing variant (Table
2). Copy number variations were identiﬁed in 3 pa-
tients, 2 had a deletion of exons 2 to 18, and 1 had a
deletion of the whole LDLR coding region (Online
Table 1). Two known missense variants (Online
Table 1) and 1 novel disease-causing variant
(Table 2) were identiﬁed in APOB. In the remaining
participants without disease-causing variants, 51
(18.7%) were carriers of the hypercholesterolemia-
associated APOE E4 isoform, whereas 66 partici-
pants (24.3%) had conditions that remained
genetically undiagnosed (Table 1). A cardiovascular
complication-negative family history according to
Simone Broome Register criteria (1) was associated
with 48.6%, 60.0%, and 76.5% of patients with
disease-causing or disease-associated variants in
LDLR, APOB, or APOE E4 isoform, respectively(Table 1). Relative risk of having a disease-causing
genetic variant when a participant had a positive
family history was 1.53 (RR: 1.529; 95% CI: 1.25 to 1.88;
p ¼ 0.0001). The OR for having a disease-causing
genetic variant in participants with a TC level >6
mmol/l (231.7 mg/dl) was 7.71 compared with an OR of
7.71 (95% CI: 1.75 to 33.35; p ¼ 0.0013) for the partic-
ipants with TC levels between 5 and 6 mmol/l (193.1
and 231.7 mg/dl, respectively). Among 33 patients
with TC levels between 5 and 6 mmol/l (193.1 and
231.7 mg/dl, respectively), 2 had disease-causing var-
iants in LDLR and none in APOB. Among 177 patients
with TC levels between 6 and 8 mmol/l (231.7 and
308.9 mg/dl, respectively), 31.1% had disease-causing
variant in LDLR and 23.7% in APOB. Among 62 pa-
tients with a TC level >8 mmol/l (308.9 mg/dl), 77.4%
had disease-causing variants in LDLR and 12.9% in
APOB. Carriers of LDLR and APOB disease-causing
genetic variants had on average higher TC levels at
universal screening for hypercholesterolemia than
noncarriers (7.7  1.2 mmol/l vs. 6.6  0.9 mmol/l,
respectively [297.346.3mg/dl vs. 254.8 34.8mg/dl,
respectively]; p < 0.0001). Additionally, carriers of
LDLR and APOB disease-causing genetic variants had
on average higher concentrations of TC (7.0  1.1
mmol/l vs. 5.8  0.8 mmol/l, respectively [272.0 
43.7 mg/dl vs. 222.4  29.6 mg/dl, respectively];
p< 0.0001), LDL (5.2 1.2 mmol/l vs. 3.8 0.8 mmol/l,
respectively [198.9 45.5 mg/dl vs. 145.4  29.1 mg/dl,
respectively]; p < 0.0001), and non-HDL (5.6  1.2
mmol/l vs. 4.3  0.8 mmol/l, respectively [217.3  45.0
mg/dl vs. 164.9 31.3 mg/dl, respectively]; p< 0.0001)
upon initial evaluation at the tertiary pediatric out-
patient clinic than noncarriers. Associations among
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1255sex, serum TC levels, standard deviation score of body
mass index, and presence of causative genetic variants
in LDLR and APOB were not statistically signiﬁcant.
DISCUSSION
This is the ﬁrst study to evaluate genetic identiﬁcation
of FH by a national universal screening for hypercho-
lesterolemia. Children were screened at 5 years of age,
yet the mean referral age to the tertiary pediatric
outpatient clinic was 7.3 years of age, indicating the
requirement of additional educational intervention to
promote more rapid referral of patients from primary
care institutions for further clinical evaluation, along
with a record of children not referred or whose parents
refused referral. Serum TC level discriminates best
between people with and without FH in the interval
from 1 to 9 years of age, making it the optimal period
for universal screening for hypercholesterolemia.
Serum TC can identify 88.0% to 96.0% of cases, with a
false positive rate between 0.1% and 1.0% (21). In
addition, once an affected child is identiﬁed, 96.0% of
parents with the disorder could be detected by iden-
tifying the parent with the higher cholesterol level
(child–parent screening strategy) (22). All parents and
older siblings from children identiﬁed as having FH in
our study were referred for evaluation. The simulated
detection rate of FH in our national universal
screening for hypercholesterolemia on the basis of
commonly reported incidence of 1 in 500 was more
than 96.0% in the last year and allowed for a reliable
identiﬁcation of the risk population. Nevertheless,
when an incidence rate of 1 in 200 is assumed, only
38.5% of the at-risk population was detected. An
estimation of the total population enrolled in the na-
tional universal screening from 2009 to 2013 indicated
that only approximately one-half of the total popula-
tion was reached. Consequently, continuation and
further improvements of screening and referral stra-
tegies will provide more data for the real FH incidence
in the Slovenian population and improve clinical al-
gorithms in FH riskmanagement. The optimal age for a
universal screening for hypercholesterolemia remains
to be determined (15). Early dietary and lifestyle
intervention along with cholestyramine assessment
at 6 years of age (23) and use of statins after 8 years of
age (24) in FH are beneﬁcial, and therefore a diagnosis
and intervention before pubertal age seems prudent
(4,15,18).
A disease-causing genetic variant for FH was
identiﬁed in 57% of participants referred from the
universal screening, with an additional one-ﬁfth
identiﬁed with the most common multifactorial
form of hypercholesterolemia, amounting to >75.0%of referred participants carrying a disease-causing or
disease-associated genetic variant. Proportions of
disease-causing variants in the present study were on
the lower end of reported population data for LDLR
and on the higher end in the same reports for APOB.
For Czech (25), Polish (26), French (27), Spanish (28),
and Italian (29) populations, the reported disease-
causing variant frequencies were 23.9%, 45.0%,
73.9%, 96.4%, and 97.4%, respectively, and were
11.8%, 6.0%, 6.6%, 3.5%, and 2.2%, respectively, for
APOB. Lack of the disease-causing PCSK9 variant in
the Slovenian population was similar to that in the
Finnish (30) and Greek (31) populations. The LDLR
and APOB spectra of disease-causing variants are
diverse. In large countries such as Italy (29), Spain
(28), France (27), or Poland (25), more than 100
disease-causing variants contribute to a heteroge-
neous pool, whereas in populations such as those in
Finland (30) or Iceland (32), the diversity of disease-
causing variants is smaller, with less than 10
disease-causing variants present. Thirty-three dis-
ease-causing variants were identiﬁed in LDLR in the
Slovenian cohort, 6 of which explained 55.2% of
LDLR-positive cases. Two disease-causing variants
were identiﬁed in APOB. One of these (p.Arg3527Gln)
explained 96.0% of APOB-positive cases, probably
due to its central European origin and a known
migration patterns of carriers (33). Approximately
6.0% of disease-causing variants in LDLR and APOB
were novel, conﬁrming the wide variety of variants
associated with the disease in other populations (4).
Almost one-ﬁfth of the total cohort was negative
for disease-causing variants in LDLR, APOB, and
PCSK9 but carried the APOE E4 isoform, emphasizing
the potential contribution of APOE genetic variants in
the multifactorial cause of hypercholesterolemia (13).
The remaining 24.3% of patients in the present study
had no disease-causing or disease-associated variants
identiﬁed, which is in accordance with other reports
in which 10.0% to 40.0% (depending on the inclusion
criteria) of those with clinical diagnosis of FH were
found not to be carriers of disease-causing genetic
variants in LDLR, APOB, or PCSK9 and were likely to
have a polygenic or multifactorial type of hypercho-
lesterolemia (28,34).
A signiﬁcant advantage in cost reduction
(approximately 3-fold decrease for the central Euro-
pean region) and timely identiﬁcation of causative
genetic variants (approximately 7-fold reduction in
turnaround time in our laboratory) with the NGS
compared with more widely used genetic screening
methods (35) (e.g., denaturing high-pressure liquid
chromatography or high resolution DNA melting
analysis and Sanger sequencing) were observed.
PERSPECTIVES
COMPETENCY IN SYSTEMS-BASED PRACTICE:
Screening for hypercholesterolemia in children at
5 years of ages for familial hypercholesterolemia (FH)
identiﬁed disease-causing variants in genes for LDLR
and APOB in almost two-thirds of participants, and
one-ﬁfth were carriers of disease-associated variant
encoding APOE E4 isoform. These data support pro-
posals by the National Heart, Lung, and Blood Institute,
National Lipid Association Expert Panel in the United
States, and the European Expert Panel for universal
screening as a preferred method of identifying FH as
part of comprehensive primary prevention efforts.
TRANSLATIONAL OUTLOOK: Larger conﬁrmatory
studies are needed to determine the optimum timing
and strategy for universal screening for FH using an
expanded panel of FH-associated genes, and to deﬁne
long-term efﬁcacy and cost-effectiveness of this
population-based approach.
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1256Moreover, NGS reduced the possibility of human errors
due to reduced hands-on time per sample (36).
A 56.0% diagnostic yield and a signiﬁcant associa-
tion of tendon xanthoma and LDL-cholesterol level
with the disease-causing LDLR or APOB variant has
been demonstrated in an adult cohort (34). Compa-
rable diagnostic yield in the adult population with
clinical presentation of hypercholesterolemia (34)
and our pediatric population without any clinical
signs indicates that a universal screening may be an
efﬁcacious strategy for early detection of FH and
prevention of cardiovascular complications. Impor-
tantly, almost one-half of participants with a TC level
<6 mmol/l (231.7 mg/dl) carried a disease-causing or
disease-associated genetic variant. Furthermore, a
cardiovascular complications-negative family history
according to Simone Broome Register criteria (1) was
observed in one-half to three-quarters of patients
with a disease-causing or disease-associated variant
in LDLR, APOB, or the APOE E4 isoform. The RR of
having a disease-causing variant with a positive
family history was signiﬁcant but relatively low. Data
for a family history may not always be a reliable in-
dicator for identiﬁcation of potential FH patients (37).
STUDY LIMITATIONS. This study was limited by a
relatively small Slovenian population, as well as
gradual implementation of the universal national
screening for hypercholesterolemia. More data are
required to optimize and evaluate the universal
screening criteria and referral strategy. Additionally,
a cascade screening for parents and siblings of iden-
tiﬁed affected children should be envisaged.
CONCLUSIONS
Results from the present study demonstrated for
the ﬁrst time that a national universal screening
for hypercholesterolemia at 5 years of age identiﬁed
genetically conﬁrmed FH in more than one-half of the
referred participants. Moreover, a genetic variant in
APOE associated with hypercholesterolemia was
detected in an additional one-ﬁfth of the referred
participants. Data for family history may not sufﬁce
for reliable identiﬁcation of patients throughselective screening. Our ﬁndings support the latest
recommendations by professional forums for a uni-
versal screening for hypercholesterolemia in chil-
dren. Coupled with a cascade screening for family
members, universal screening for hypercholesterole-
mia could be a powerful approach for FH detection
and prevention of cardiovascular complications.
Additional studies are warranted to conﬁrm the re-
sults of this study.
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